TEAEs in ≥15% of patients
| TEAE . | Total (N = 35) . | ||
|---|---|---|---|
| All grades, n (%) . | Grade 3, n (%) . | Grade 4, n (%) . | |
| Any AE | 34 (97) | 16 (46) | 8 (23) |
| Hematologic | |||
| Neutropenia | 7 (20) | 3 (9) | 3 (9) |
| Investigations | |||
| ALT/AST increased | 20 (57) | 11 (31) | 3 (9) |
| Blood alkaline phosphatase increased | 6 (17) | 0 | 0 |
| Blood creatinine increased | 6 (17) | 0 | 0 |
| Nonhematologic | |||
| Pyrexia | 13 (37) | 0 | 0 |
| Cough | 12 (34) | 0 | 0 |
| Diarrhea | 11 (31) | 0 | 0 |
| Fatigue | 11 (31) | 3 (9) | 0 |
| Nausea | 9 (26) | 0 | 0 |
| Weight decrease | 9 (26) | 0 | 0 |
| Headache | 8 (23) | 0 | 0 |
| Maculopapular rash | 8 (23) | 6 (17) | 0 |
| Chills | 6 (17) | 0 | 0 |
| Constipation | 6 (17) | 0 | 0 |
| Dyspnea | 6 (17) | 3 (9) | 1 (3) |
| Pneumonia* | 8 (23) | 5 (14) | 1 (3) |
| Wheezing | 6 (17) | 0 | 0 |
| TEAE . | Total (N = 35) . | ||
|---|---|---|---|
| All grades, n (%) . | Grade 3, n (%) . | Grade 4, n (%) . | |
| Any AE | 34 (97) | 16 (46) | 8 (23) |
| Hematologic | |||
| Neutropenia | 7 (20) | 3 (9) | 3 (9) |
| Investigations | |||
| ALT/AST increased | 20 (57) | 11 (31) | 3 (9) |
| Blood alkaline phosphatase increased | 6 (17) | 0 | 0 |
| Blood creatinine increased | 6 (17) | 0 | 0 |
| Nonhematologic | |||
| Pyrexia | 13 (37) | 0 | 0 |
| Cough | 12 (34) | 0 | 0 |
| Diarrhea | 11 (31) | 0 | 0 |
| Fatigue | 11 (31) | 3 (9) | 0 |
| Nausea | 9 (26) | 0 | 0 |
| Weight decrease | 9 (26) | 0 | 0 |
| Headache | 8 (23) | 0 | 0 |
| Maculopapular rash | 8 (23) | 6 (17) | 0 |
| Chills | 6 (17) | 0 | 0 |
| Constipation | 6 (17) | 0 | 0 |
| Dyspnea | 6 (17) | 3 (9) | 1 (3) |
| Pneumonia* | 8 (23) | 5 (14) | 1 (3) |
| Wheezing | 6 (17) | 0 | 0 |
Includes all events of lung infections, viral and bacterial pneumonia, including 1 event of HSV pneumonia (grade 5).